NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free CGON Stock Alerts $32.58 -1.71 (-4.99%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share Today's Range$31.81▼$34.4150-Day Range$25.84▼$43.9052-Week Range$25.77▼$50.23Volume1.53 million shsAverage Volume687,960 shsMarket Capitalization$2.17 billionP/E RatioN/ADividend YieldN/APrice Target$63.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get CG Oncology alerts: Email Address CG Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.7% Upside$63.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.71) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector811th out of 924 stocksBiological Products, Except Diagnostic Industry139th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCG Oncology has only been the subject of 3 research reports in the past 90 days.Read more about CG Oncology's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CGON. Previous Next 0.0 Dividend Strength Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGON. Previous Next 3.1 News and Social Media Coverage News SentimentCG Oncology has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CG Oncology this week, compared to 4 articles on an average week.Search Interest8 people have searched for CGON on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.71) to ($1.97) per share.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CG Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About CG Oncology Stock (NASDAQ:CGON)CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More CGON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGON Stock News HeadlinesJune 2 at 2:22 AM | americanbankingnews.comCG Oncology (NASDAQ:CGON) Shares Gap Down to $34.29May 29, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for CG Oncology (NASDAQ:CGON)May 26, 2024 | americanbankingnews.comCG Oncology (NASDAQ:CGON) Stock Price Up 5.1%May 24, 2024 | msn.comCG Oncology climbs 10% on Phase 2 data for bladder cancer drugMay 24, 2024 | globenewswire.comCG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingMay 14, 2024 | markets.businessinsider.comDecoding 10 Analyst Evaluations For CG OncologyMay 14, 2024 | msn.comGoldman Sachs Upgrades CG Oncology (CGON)May 10, 2024 | markets.businessinsider.comBuy Rating for CG Oncology on Strong Trial Results and Market PotentialMay 9, 2024 | globenewswire.comCG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | markets.businessinsider.comCG Oncology’s Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy RatingMay 6, 2024 | seekingalpha.comCG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further ValueMay 4, 2024 | markets.businessinsider.comBuy Rating Justified by CG Oncology’s Cretosmogene Efficacy and Market PositioningMay 3, 2024 | seekingalpha.comCG Oncology reports data from Phase 3 bladder cancer studyMay 3, 2024 | seekingalpha.comCG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage TrialsMay 3, 2024 | globenewswire.comCretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerApril 26, 2024 | globenewswire.comCG Oncology to Host Virtual Investor Event on Friday, May 3, 2024April 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - CGONApril 24, 2024 | globenewswire.comCG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024April 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG ShortageApril 16, 2024 | finance.yahoo.comCG Oncology, Inc. (CGON)April 12, 2024 | msn.com20 Countries with the Most Domestically Listed Companies in the WorldApril 5, 2024 | investing.comCG Oncology Inc (CGON)April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology on Strong Clinical Data and Market PotentialApril 1, 2024 | markets.businessinsider.comBuy Rating Justified by CG Oncology’s Strong Clinical Trial Results and Promising Cretosimogene TherapyMarch 28, 2024 | globenewswire.comCG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingSee More Headlines Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CUSIPN/A CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$63.75 High Stock Price Target$75.00 Low Stock Price Target$50.00 Potential Upside/Downside+95.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio57.95 Quick Ratio57.95 Sales & Book Value Annual Sales$200,000.00 Price / Sales10,855.66 Cash FlowN/A Price / Cash FlowN/A Book Value$8.54 per share Price / Book3.81Miscellaneous Outstanding Shares66,640,000Free FloatN/AMarket Cap$2.17 billion OptionableOptionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Arthur Kuan (Age 33)Chairman & CEO Comp: $640.97kMr. Ambaw Bellete M.S. (Age 53)President & COO Comp: $1.06MDr. Vijay Kasturi M.D. (Age 56)Chief Medical Officer Comp: $212.24kMs. Corleen M. Roche (Age 57)CFO & Secretary Ms. Amy SteeleVice President of Finance, Accounting & AdministrationMr. Swapnil Bhargava Ph.D.Chief Technical OfficerMr. Bing KungVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsRepligenNASDAQ:RGENVaxcyteNASDAQ:PCVXRevolution MedicinesNASDAQ:RVMDExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 1,397,433 shares on 5/17/2024Ownership: 2.097%BVF Inc. ILBought 1,884,191 shares on 5/16/2024Ownership: 2.827%Janus Henderson Group PLCBought 1,521,432 shares on 5/16/2024Ownership: 2.283%Blackstone Inc.Bought 25,000 shares on 5/16/2024Ownership: 0.038%California State Teachers Retirement SystemBought 2,341 shares on 5/16/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions CGON Stock Analysis - Frequently Asked Questions Should I buy or sell CG Oncology stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CG Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGON shares. View CGON analyst ratings or view top-rated stocks. What is CG Oncology's stock price target for 2024? 4 analysts have issued 1 year target prices for CG Oncology's shares. Their CGON share price targets range from $50.00 to $75.00. On average, they expect the company's stock price to reach $63.75 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for CGON or view top-rated stocks among Wall Street analysts. How have CGON shares performed in 2024? CG Oncology's stock was trading at $37.17 at the beginning of 2024. Since then, CGON stock has decreased by 12.3% and is now trading at $32.58. View the best growth stocks for 2024 here. When is CG Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CGON earnings forecast. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) issued its earnings results on Thursday, May, 9th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.01. The business earned $0.53 million during the quarter. What ETF holds CG Oncology's stock? Goldman Sachs Future Health Care Equity ETF holds 4,986 shares of CGON stock, representing 0.63% of its portfolio. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. When does CG Oncology's lock-up period expire? CG Oncology's lock-up period expires on Tuesday, July 23rd. CG Oncology had issued 20,000,000 shares in its initial public offering on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. After the expiration of CG Oncology's lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Who are CG Oncology's major shareholders? CG Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Decheng Capital LLC (8.19%), Vanguard Group Inc. (3.34%), BVF Inc. IL (2.83%), Janus Henderson Group PLC (2.28%), RA Capital Management L.P. (2.10%) and Price T Rowe Associates Inc. MD (1.49%). Insiders that own company stock include Corleen M Roche, Decheng Capital Global Life Sc, Hong Fang Song and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGON) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.